01 7Cipralex/Lexapro
02 6Lexapro
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 387
2019 Revenue in Millions : 376
Growth (%) : 3
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 139
2019 Revenue in Millions : 137
Growth (%) : 1
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 130
2020 Revenue in Millions : 137
Growth (%) : 2
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 358
2020 Revenue in Millions : 381
Growth (%) : -1
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 340
2021 Revenue in Millions : 358
Growth (%) : -5
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 89
2021 Revenue in Millions : 130
Growth (%) : -31
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 308
2022 Revenue in Millions : 340
Growth (%) : -10
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 3
2022 Revenue in Millions : 89
Growth (%) : -97
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 403
2016 Revenue in Millions : 428
Growth (%) : -6
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 339
2017 Revenue in Millions : 359
Growth (%) : -6%
LOOKING FOR A SUPPLIER?